• S&P 500: 1,351.95
  • Change: 0.15%
$2.05 -0.02 (-0.97%)
2/9/2012 4:00 PM

Geron Corp (NASDAQ:GERN)

CAPS Rating: 3 out of 5

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.

Current Price $2.05 Mkt Cap $269.42M
Open $0.00 P/E Ratio 0.00
Prev. Close $2.07 Div. (Yield) N/A (N/A)
Daily Range $2.04 - $2.09 Volume 456,731
52-Wk Range $1.35 - $5.24 Avg. Daily Vol. 0

News & Discussion Boards

Caps

How do you think GERN will perform against the market?

You must Sign in to MSN Caps before you can make a call.

All Players

618 Outperform
55 Underperform
 

All-Star Players

111 Outperform
16 Underperform
 

Wall Street

6 Outperform
1 Underperform
 

Top GERN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.31)
Submitted December 29, 2011

It's been a bad second half of 2011 for Geron. In May they had a bloated market cap over 600M, two early stage cancer drugs, and a stuttering stem cell program for spinal cord injury. Over the next few months the share price declined as it became… More

Add Comment | Reply | Report this Post

SwingCorey (52.83)
Submitted January 11, 2010

Embryonic stem cell research, regardless of the current presidential/congressional support, is in trouble. They have not figured out how to fix the problems (e.g. cancerous tumors), yet "adult" stem cells (e.g., from dental pulp, bone marrow, and… More

2 Comments | Reply | Report this Post
GERN VS S&P 500 (SPY)

Fools bullish on GERN are also bullish on:

Fools bearish on GERN are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about GERN.

Recs

1
Member Avatar zzlangerhans (99.31) Submitted: 12/29/2011 12:31:32 AM : Outperform Start Price: $1.43 GERN Score: +35.68

It's been a bad second half of 2011 for Geron. In May they had a bloated market cap over 600M, two early stage cancer drugs, and a stuttering stem cell program for spinal cord injury. Over the next few months the share price declined as it became clear that stem cell therapies are still highly speculative, and Geron's program in particular was listing heavily. In November, the share price reached new all-time lows after the company announced that they would be shelving their stem cell programs until further notice in order to concentrate resources on taxane derivative GRN1005 and telomerase inhibitor imetelstat.

Now that the dust has cleared, Geron's stock is still on the ropes giving the company an enterprise value of 44M for the two phase II oncology programs. Imetelstat in particular is encouraging, with phase II data in NSCLC, breast cancer, essential thrombocytopenia, and multiple myeloma expected before the end of 2012. Two phase II trials of GRN1005 were recently initiated as well. There's no guarantee that either of these drugs will bring phase II success, but with 142M in cash Geron has the resources to bring this story to a conclusion.

Report this Post Add Comment | Reply | Permalink

Recs

0
Member Avatar portefeuille (99.84) Submitted: 12/15/2011 11:15:02 PM : Outperform Start Price: $2.57 GERN Score: -31.96

There are currently 11000 GERN shares in my "fund" with break-even of around 2.65 USD. http://caps.fool.com/Blogs/fund-trades/678775.

Report this Post Add Comment | Reply | Permalink

Recs

0
Member Avatar KimLanners (< 20) Submitted: 11/15/2011 7:18:24 PM : Underperform Start Price: $1.68 GERN Score: -13.57

down

Report this Post Add Comment | Reply | Permalink
View All 157 Pitches »

Leaderboard

Find the members with the highest scoring picks in GERN.

Score Leader

SheepInvstr213

SheepInvstr213 (< 20) Score: +190.97

The Score Leader is the player with the highest score across all their picks in GERN.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		Index
Gain 		Score Commentary
SheepInvstr213 < 20 3/9/2009 Underperform 5Y $4.59 -55.36% +101.44% +156.80 0 Comment
mmmed 29.71 3/3/2009 Underperform NS $3.87 -46.96% +96.80% +143.76 0 Comment
epc53 84.73 3/3/2009 Underperform NS $3.85 -46.75% +95.46% +142.21 0 Comment
js2776 < 20 1/26/2009 Underperform 3Y $8.15 -74.85% +64.61% +139.46 2 Comments
kevleeyang 83.10 1/23/2009 Underperform NS $7.23 -71.65% +66.18% +137.83 0 Comment
Dudeone 97.35 3/12/2009 Underperform 5Y $4.32 -52.55% +85.10% +137.64 0 Comment
Lafleur526 43.82 1/26/2009 Underperform 3W $7.47 -72.56% +64.79% +137.35 0 Comment
yourfavoritepers 80.11 1/26/2009 Underperform 3W $7.47 -72.56% +64.79% +137.35 0 Comment
dcfoolz 75.05 1/26/2009 Underperform 5Y $7.47 -72.56% +64.79% +137.35 0 Comment
SheepInvstr321 76.70 1/23/2009 Underperform 5Y $7.36 -72.14% +64.51% +136.66 0 Comment
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
trackwbbsecuriti 39.18 11/16/2011 Outperform NS $1.68 +22.02% +8.45% +13.57 0 Comment
TrackRodmanRen < 20 1/23/2009 Outperform NS $7.04 -70.88% +69.43% -140.31 0 Comment
trackmerriman 70.87 12/11/2008 Outperform NS $4.29 -52.21% +53.48% -105.69 0 Comment
TrackUBS 93.25 1/29/2008 Outperform NS $5.00 -59.00% +3.65% -62.65 0 Comment
TrackEveillard 96.01 9/30/2007 Outperform NS $7.32 -71.99% -7.05% -64.94 2 Comments
TrackTobinSmith < 20 11/11/2006 Outperform 1Y $8.59 -76.14% +3.93% -80.07 0 Comment
TrackJimCramer 78.02 3/24/2006 Underperform 3W $8.33 -75.39% +11.39% +86.78 0 Comment

Featured Broker Partners